



OMICS Group International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over 400 leading-edge peer reviewed Open Access Journals and organizes over 300 International Conferences annually all over the world. OMICS Publishing Group journals have over 3 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 30000 eminent personalities that ensure a rapid, quality and quick review process. OMICS Group signed an agreement with more than 1000 International Societies to make healthcare information Open Access.

OMICS Journals are welcoming Submissions

OMICS Group welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way.

OMICS Journals are poised in excellence by publishing high quality research. OMICS Group follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.


Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions.


The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.


For more details please visit our website: http://omicsonline.org/Submitmanuscript.php




Multifunctional Targeted Nanocarriers for Cancer Therapy











Mahavir B. Chougule, Ph.D.

Assistant Professor
The Daniel K. Inouye College of Pharmacy,
University of Hawaii at Hilo
Hilo, HI, 96720 USA.





NANOtech based Delivery Explorations

Overall Research Goal

Development of nanotechnology based systems for targeted delivery of small molecules, siRNA, plasmid DNA, and proteins for the treatment of various cancers, asthma and skin disorders.

Research Focus


- Lung and Breast Cancer
- Neuroblastoma
- Mesothelioma
- Asthma
- Topical and Transdermal delivery




Formulation of Nanocarriers

Rational for Therapeutic Agents

Therapeutic Agents






- Etoposide
- DFMO
- Onconase
- Small molecule drugs




Formulation of Nanocarriers

Rational for Nanocarrier systems


Gelatin, Albumin, Chitosan, PLGA based Targeted Hybrid Nanocarriers



Hydrophobic & Hydrophilic Nanocarriers




Liposome Nanocarriers







Routes of Administrations


Route of Administration





Oral










Topical

Transdermal






Elicit Therapeutic Effects





Outline of Nanocarrier Development and Evaluation





Instruments

Instruments for Nanoparticle Characterization & Formulation


1) Nano Debee High Pressure Homogenizer; 2) Nicomp 380 ZLS Particle Size & Zeta Potential; 3) EasyMax 102 Crystallizer; 4) In vitro lung models; 5) HPLC; 6) Fluorescent Microscope; 7) Diffusion set up; 8) Biotek Synergy plate reader (absorbance/fluorescence/bioluminescence)

















Relevant Publications

- 1. Chougule MB, Patel AR, Sachdeva P, Jackson T, Singh M. Anti-cancer activity of noscapine, an opioid alkaloid in combination with cisplatin in human non-small cell lung cancer. *Lung Cancer*, 2011, 71(3):271-82. PMCID:PMC3094914
- 2. Ichite N, Chougule MB, Patel AR, Jackson T, Safe S, Singh M. Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer. Molecular Cancer Therapeutics 2010, 9(11):3003-14. PMCID:PMC2978798, The first two authors contributed equally
- 3. Patlolla R, Chougule MB, Patel AR, Jackson T, and Singh M. Celecoxib encapsulated nanostructured lipid carrier system for pulmonary delivery. *J Control Release* 2010, 144(2):233-41. PMCID:PMC2868936
- **4. Chougule MB**, Patel AR, Jackson T, Singh M. Antitumor activity of noscapine in combination with Doxorubicin in triple negative breast cancer. *PLoS One* 2011, 6(3):e17733. PMCID: PMC3057970
- **5. Chougule MB*,** Tekade RK (2012) Current Scene and Prospective Potentials of siRNA in Cancer Therapy. *J Pharmacogenom Pharmacoproteomics* 3:e125.
- **6. Chougule MB*,** Tekade RK, Hoffmann PR, Bhatia D, Pathak Y, Chapter 12, Nanomaterial Based Gene and Drug Delivery: Pulmonary Toxicity Considerations, *Bio-interactions of Nano materials*, 2013, Taylor and Francis, Boca Raton, Florida, USA. *In Press*.
- 7. Patel AR, **Chougule MB***, Ian T, Patlolla RR, Guangdi W, Singh M*. Efficacy of Aerosolized Celecoxib Encapsulated Nanostructured Lipid Carrier in Non-small Cell Lung Cancer in combination with Docetaxel, *Pharm Res.* 2013 Jan 30. [Epub ahead of print] PMC Journal In Process
- 8. Kolate A, **Chougule MB***, Chapter 13, Application of polymers in lung drug delivery, *Applications of Polymers in Drug Delivery*, Smithers Rapra Publishers, Shawbury, Shrewsbury, Shropshire, SY4 4NR, UK, 2013, *In Press* * Corresponding author

Pharmacovigilance Related Journals

- Journal of Molecular and Genetic Medicine
- Journal of Data Mining in Genomics & Proteomics
- Journal of Proteomics & Bioinformatics



Pharmacovigilance Related Conferences

- > 2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics
- > 4th International Conference on Proteomics & Bioinformatics
- > 2nd International Conference on Genomics & Pharmacogenomics





